Funding for this research was provided by:
VINNOVA (2017-02130, 2017-02453)
Received: 17 February 2022
Accepted: 6 October 2022
First Online: 19 October 2022
: Informed consent was obtained from the participants. The study was approved by the Swedish Ethical Review Authority (Dnr 2019-06539). All methods were performed in accordance with the relevant guidelines and regulations (e.g., Declaration of Helsinki).
: HW has received compensation for education activities from pharmaceutical companies (Bristol Meyer Squibb, Abbott, Abbvie) and performed clinical studies with Herantis Pharma Y/O, Renishaw Ltd, and served as an advisor to Novo Nordisk A/S on the use of pluripotent stem cell for clinical use in humans. Other authors declare no competing interests.